Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Nine months ended February 28, 2025 (Fiscal Year 2025)
Business Overview: Biomerica is a global biomedical technology company developing diagnostic and therapeutic products, primarily focusing on gastrointestinal diseases (e.g., inFoods® IBS) and point-of-care testing. The company operates manufacturing facilities in the U.S. and Mexico, with sales distributed globally.
Key Financial Metrics
| Metric | Three Months Ended Feb 28, 2025 | Nine Months Ended Feb 28, 2025 |
|---|---|---|
| Net Sales | $1,119,000 | $4,562,000 |
| Gross Profit | $19,000 (1.7% margin) | $742,000 (16.3% margin) |
| Net Loss | $(1,163,000) | $(3,429,000) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.18) |
| Cash and Cash Equivalents | $3,058,000 (as of Feb 28, 2025) | |
| Working Capital | ||
| Total Liabilities | $1,842,000 | |
| Accumulated Deficit | $(51,624,000) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% ($102,000) for the three months and 6% ($263,000) for the nine months compared to the prior year periods. Growth was driven by increased contract manufacturing billings and demand for the inFoods® IBS product, offset by a 48% decline in Over-the-Counter (OTC) sales for the quarter.
- Cost Reductions: Operating expenses decreased significantly due to a 15% workforce reduction (Reduction in Force) executed in July 2024.
- Selling, General & Administrative (SG&A): Decreased 33% ($496,000) for the quarter and 16% ($660,000) for the nine months.
- Research & Development (R&D): Decreased 37% ($126,000) for the quarter and 37% ($455,000) for the nine months.
- Gross Margin Improvement: Gross profit turned positive for the quarter ($19,000) compared to a loss of $(149,000) in the prior year quarter, largely due to reduced labor costs.
- Financing Activity: The company raised approximately $2.015 million in net proceeds through an At-The-Market (ATM) offering during the nine-month period, compared to no equity financing in the prior year period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash balances ($3.058 million) are deemed insufficient to meet operating requirements for the next twelve months without additional financing or revenue growth.
- Strategic Initiatives: The company is pursuing cost-cutting measures, selling non-core assets, and seeking additional debt or equity financing. Commercialization efforts are focused on the inFoods® IBS product and the new hp+detect™ test for H. pylori.
- Liquidity Constraints: Future capital raising via the ATM offering is constrained by low stock trading volumes and prices (ranging from $0.27 to $1.03 recently).
- Risks: Key risks include the need for additional capital, dependence on a few key customers (one customer accounted for 35% of nine-month sales), and potential impacts from international trade policies and tariffs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.058 million cash balance against the reported quarterly cash burn rate (approx. $800,000 excluding ATM proceeds) to assess immediate liquidity risk.
- ATM Offering Viability: Monitor stock price and volume trends to determine the feasibility of raising further capital through the existing $5.5 million ATM facility.
- Customer Concentration: Review the stability of the top customer in Asia, which accounted for 35% of nine-month sales, and the top three customers (61% of quarterly sales).
- Product Commercialization: Assess the traction of the inFoods® IBS and hp+detect™ products to determine if they can generate sufficient revenue to offset the high operating cost structure.
- Inventory Levels: Note the reduction in inventory from $2.376 million to $1.655 million; verify if this reflects improved efficiency or reduced production capacity.